%0 Journal Article
%T Real-world treatment patterns among patients with advanced gastric cancer in Russia: a chart review study
%A Alexey A. Tryakin
%A Diego Novick
%A Evgeniya Sholokhova
%A Jasmina I. Ivanova
%A Luke M. Schmerold
%A Natalia S. Besova
%A Philippe Thompson-Leduc
%A Sergei A. Tjul
%A Wendy Y. Cheng
%A in
%J Journal of Drug Assessment
%D 2019
%R https://doi.org/10.1080/21556660.2019.1669610
%X Abstract Objective: Little evidence is available on the management of patients with metastatic and/or unresectable gastric cancer (mGC) after the failure of first-line treatment. This study presents real-world data on characteristics and treatment patterns of patients with mGC in Russia. Methods: Eligible patients were ¡Ý18 years old, diagnosed with mGC£¿¡Ý£¿January 1, 2012, received first-line chemotherapy followed by second-line chemotherapy or best supportive care (BSC), had ¡Ý3£¿months of follow-up after the start of second-line chemotherapy or BSC (except in cases of death), and had not participated in a clinical trial. Data were summarized using descriptive statistics. Results: A total of 88 physicians provided data from 202 charts. Mean age at mGC diagnosis was 53.7 (standard deviation: 11.2) years; 70.8% of patients were male. Reasons for first-line treatment discontinuation included disease progression (50.5%) and adverse events/toxicity (39.1%). There were 52 unique treatment regimens prescribed in second-line; capecitabine (14.5%), paclitaxel (9.3%), and capecitabine£¿+£¿oxaliplatin (8.7%) were the most frequent. Reasons for second-line treatment discontinuation included disease progression (39.8%) and patient refusal to continue (37.5%). During 2nd-line treatment, the most common treatment-related symptoms were nausea/vomiting (75.0%), while pain (73.8%) was the most common disease-related symptom. Antiemetics (63.4%), chemotherapy (61.6%), non-narcotic analgesics (48.3%), endoscopy (45.9%), and nutritional support (35.5%) were most frequently used as supportive care. Conclusions: Second-line treatment patterns for patients with mGC in Russia are heterogeneous. Results of this study indicate the need for more intensive implementation of the most active regimens in second-line treatment of mGC according to international and national guidelines
%U https://www.tandfonline.com/doi/full/10.1080/21556660.2019.1669610